Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

20 trials with published results (54%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

5.4%

2 terminated out of 37 trials

Success Rate

93.3%

+6.7% vs benchmark

Late-Stage Pipeline

38%

14 trials in Phase 3/4

Results Transparency

71%

20 of 28 completed with results

Key Signals

20 with results93% success

Data Visualizations

Phase Distribution

37Total
Not Applicable (1)
P 1 (7)
P 2 (15)
P 3 (10)
P 4 (4)

Trial Status

Completed28
Withdrawn3
Unknown2
Terminated2
Recruiting2

Trial Success Rate

93.3%

Benchmark: 86.6%

Based on 28 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT07681271Phase 2RecruitingPrimary

A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

NCT06013371Phase 2Terminated

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

NCT04731259Phase 1Withdrawn

Study to Evaluate the Safety of ATR-04

NCT06952517Phase 2Recruiting

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

NCT06532136Phase 2WithdrawnPrimary

Deucravacitinib Rosacea

NCT03883945Phase 1WithdrawnPrimary

A Safety and Efficacy Study to Evaluate Rosacea

NCT05296629Phase 3CompletedPrimary

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05343455Phase 3CompletedPrimary

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05150587Phase 2CompletedPrimary

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

NCT05838170Phase 2CompletedPrimary

Study of TP-04 in Participants With Papulopustular Rosacea

NCT01555463Phase 3CompletedPrimary

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT00417937Phase 4CompletedPrimary

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

NCT01257919Phase 1CompletedPrimary

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT05675501Phase 1CompletedPrimary

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT02268474Not ApplicableCompleted

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

NCT02075671Phase 4Completed

Photodynamic Therapy for Papulopustular Rosacea

NCT01872715Phase 4CompletedPrimary

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

NCT03276936Phase 3CompletedPrimary

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03564119Phase 3CompletedPrimary

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

NCT03564145Phase 3TerminatedPrimary

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Scroll to load more

Research Network

Activity Timeline